Michał Jarząb

The Maria Sklodowska-Curie National Research Institute of Oncology — Poland

Medicine · Health Sciences

30h-index2.9kcitations208works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Thyroid Cancer Diagnosis and Treatment(38), Breast Cancer Treatment Studies(25), Advanced Breast Cancer Therapies(24), Cancer Treatment and Pharmacology(18), HER2/EGFR in Cancer Research(17)

Publications208 total

Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors
BMC Cancer·2026Open Access
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study
Journal of Neuro-Oncology·2026
Reluctance to Use a Psycho-Oncology Mobile App Among Patients With Primary Breast Cancer: Retrospective Cross-Sectional Survey
JMIR mhealth and uhealth·2025Open Access
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel
Breast Cancer Research·2025Open Access
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety
Cancer Chemotherapy and Pharmacology·2025Open Access
Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights
Supportive Care in Cancer·2025Open Access
Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis
Breast Cancer Research and Treatment·2025· 1 citedOpen Access
First real-world experience with 1L pembrolizumab and chemotherapy treatment for advanced triple-negative breast cancer in Poland: safety analysis and first survival outcomes from a multicenter cohort
2025Open Access
544P Baseline breast tumor FDG-PET metabolic activity predicts progression-free survival in HER2-positive de novo metastatic breast cancer receiving first-line THP
Annals of Oncology·2025
566P Effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer: A real-world retrospective cohort study from central Europe
Annals of Oncology·2025· 1 citedOpen Access
640eP First real-world experience with first-line pembrolizumab-based treatment for advanced triple-negative breast cancer in Poland: A multicenter analysis
Annals of Oncology·2025
Weight change and BMI are not prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in the Polish female cohort
Therapeutic Advances in Medical Oncology·2025Open Access
Abstract P4-05-02: Strategies for premedication and neutropenia prophylaxis in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights
Clinical Cancer Research·2025· 2 cited
Abstract P4-09-22: Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC)
Clinical Cancer Research·2025· 1 cited
Abstract P4-12-07: Cyclin-dependent kinase 4/6 inhibitors dose reduction in patients with endocrine resistant advanced breast cancer experiencing early disease progression
Clinical Cancer Research·2025
Positron-emission tomography utility for progression-free survival prediction in HER2-positive advanced breast cancer patients treated with pertuzumab, trastuzumab, and docetaxel.
Journal of Clinical Oncology·2025
Hemoglobin level and neutrophil-to-lymphocyte ratio as prognostic peripheral blood markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in Polish female cohort.
Journal of Clinical Oncology·2025· 1 cited
Sacituzumab govitecan initial dose reduction in Polish patients with metastatic triple-negative breast cancer: Impact on efficacy and safety.
Journal of Clinical Oncology·2025
Assessment of weight change and BMI as prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in a Polish female cohort.
Journal of Clinical Oncology·2025· 1 cited
380P Positron emission tomography prognostic utility in HER2-positive advanced breast cancer patients starting treatment with TPH regimen
ESMO Open·2025Open Access
page 1 of 11Next →

Frequent Co-authors

Barbara Jarząb(29), Małgorzata Oczko‐Wojciechowska(19), Dariusz Lange(16), Ewa Chmielik(15), Agnieszka Czarniecka(13), Jolanta Krajewska(13), Małgorzata Kowalska(12), Daria Handkiewicz-Junak(12), Dagmara Rusinek(11), Tomasz Tyszkiewicz(11), Michał Świerniak(8), Beata Kos‐Kudła(8), Leszek Królicki(8), Tomasz Bednarczuk(8), Alicja Hubalewska‐Dydejczyk(8), Grzegorz Kamiński(8), Aldona Kowalska(8), Sylwia Szpak‐Ulczok(7), Monika Kowal(7), Aleksandra Kukulska(7)